Literature DB >> 34522131

Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis.

Jinzhi Meng1, Xing Huang1, Yue Qiu1, Miao Yu2, Jinfeng Lu2, Jun Yao1.   

Abstract

BACKGROUND: Skin cutaneous melanoma (SKCM) is the most malignant tumor among skin cancers. Immunotherapy has shown a great role in the advantageous prognosis of SKCM. However, only a small percentage of people can benefit from immunotherapy. To date, there has been insufficient evidence to reveal the prognostic value of m6A in SKCM and its relationship with the infiltration of immune cells and the efficacy of immunotherapy.
METHODS: Here, we synthetically analyzed 23 m6A regulators from SKCM samples collected from the TCGA and GEO databases. We defined three m6A modification patterns and constructed m6A scores using principal component analysis (PCA).
RESULTS: We found significant differences in overall survival (OS) and immune infiltration between different m6A subclusters. Besides, m6A score was positively correlated with regulatory T-cell and helper T-cell content, which may account for the association of high m6A scores with superior prognosis. Multivariate Cox regression analysis revealed that the m6A score was an independent prognostic indicator. Moreover, patients with high m6A scores showed a better response to immunotherapy, and this result was further validated in two independent immunotherapy cohorts receiving anti-PD-1/PD-L1 therapy.
CONCLUSION: The findings suggested the m6A score can screen suitable candidates for immunotherapy and can predict immunotherapy response. This analysis of different m6A patterns in a large sample of SKCM expanded our understanding of TME and provided new ideas for prognostic assessment and personalized immunotherapy strategies for SKCM patients.
© 2021 Meng et al.

Entities:  

Keywords:  M6A-related genes; immunotherapy; prognosis; skin cutaneous melanoma

Year:  2021        PMID: 34522131      PMCID: PMC8434882          DOI: 10.2147/IJGM.S328522

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  52 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells.

Authors:  Yang Wang; Yue Li; Julia I Toth; Matthew D Petroski; Zhaolei Zhang; Jing Crystal Zhao
Journal:  Nat Cell Biol       Date:  2014-01-07       Impact factor: 28.824

Review 3.  Radiotherapy for cutaneous melanoma: current and future applications.

Authors:  Peter Gorayski; Bryan Burmeister; Matthew Foote
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

4.  Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand.

Authors:  J L Bulliard; B Cox; J M Elwood
Journal:  Cancer Causes Control       Date:  1994-05       Impact factor: 2.506

Review 5.  RNA modifications modulate gene expression during development.

Authors:  Michaela Frye; Bryan T Harada; Mikaela Behm; Chuan He
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

6.  m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.

Authors:  Seungwon Yang; Jiangbo Wei; Yan-Hong Cui; Gayoung Park; Palak Shah; Yu Deng; Andrew E Aplin; Zhike Lu; Seungmin Hwang; Chuan He; Yu-Ying He
Journal:  Nat Commun       Date:  2019-06-25       Impact factor: 14.919

Review 7.  Functions of N6-methyladenosine and its role in cancer.

Authors:  Liuer He; Huiyu Li; Anqi Wu; Yulong Peng; Guang Shu; Gang Yin
Journal:  Mol Cancer       Date:  2019-12-04       Impact factor: 27.401

8.  Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report.

Authors:  Johanna Matull; Elisabeth Livingstone; Axel Wetter; Lisa Zimmer; Anne Zaremba; Harald Lahner; Dirk Schadendorf; Selma Ugurel
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

9.  YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression.

Authors:  Yulin Shi; Songqing Fan; Mengge Wu; Zhixiang Zuo; Xingyang Li; Liping Jiang; Qiushuo Shen; Peifang Xu; Lin Zeng; Yongchun Zhou; Yunchao Huang; Zuozhang Yang; Jumin Zhou; Jing Gao; Hu Zhou; Shuhua Xu; Hongbin Ji; Peng Shi; Dong-Dong Wu; Cuiping Yang; Yongbin Chen
Journal:  Nat Commun       Date:  2019-10-25       Impact factor: 14.919

Review 10.  Systemic Therapy of Metastatic Melanoma: On the Road to Cure.

Authors:  Julian Steininger; Frank Friedrich Gellrich; Alexander Schulz; Dana Westphal; Stefan Beissert; Friedegund Meier
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639

View more
  2 in total

1.  The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.

Authors:  Yue Lv; Chun-Hui Yuan; Lu-Yao Han; Gao-Ru Huang; Ling-Ce Ju; Ling-Hui Chen; Hai-Ying Han; Chong Zhang; Ling-Hui Zeng
Journal:  Dis Markers       Date:  2022-05-14       Impact factor: 3.464

Review 2.  The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.

Authors:  Fan Chen; Xuan Xie; Min Chao; Haiyan Cao; Liang Wang
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.